In summary, while random effects on tumor carrying capacity, tumor cell proliferation rate, and CD8+ T cell proliferation half-life explain the variability in the profiles of CT26 tumors post anti-PD-(L)1 treatments, baseline tumor growth and treatment response are sensitive to both intrinsic tumor properties and immune system properties. This evidence concerns the gene CD8A and neoplasm.